NDAORALTABLET
Approved
Dec 2017
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Clinical Trials (5)
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study
Started Jun 2023
34 enrolled
Diabetes MellitusDiabetic Kidney DiseaseHypertension
Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study
Started Jun 2021
Ertugliflozin in Chronic Heart Failure
Started Mar 2021
60 enrolled
Heart Failure
Ertugliflozin for Functional Mitral Regurgitation
Started Nov 2020
128 enrolled
Mitral Valve InsufficiencyLeft Ventricular Systolic Dysfunction
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
Started Jul 2020
61 enrolled
Cardiovascular DiseasesAtherosclerosisType 2 Diabetes+1 more
Loss of Exclusivity
LOE Date
Jul 13, 2030
53 months away
Patent Expiry
Jul 13, 2030
Patent Records (1)
| Patent # | Expiry | Type | Use Code |
|---|---|---|---|
| 8080580 | Jul 13, 2030 | SubstanceProduct | U-2214 |